Cocrystal Pharma Inc. reported a fiscal‑year 2025 net loss of $8.8 million, or $0.78 per share, a significant improvement from the $17.5 million loss ($1.72 per share) recorded in 2024. The company generated zero revenue in both years, a typical profile for a clinical‑stage biopharma focused on antiviral development.
Operating cash outflow for 2025 was $8.2 million, down from $16.5 million in 2024, reflecting a disciplined cost structure. Unrestricted cash at year‑end was $7.7 million versus $9.9 million a year earlier, giving the company an estimated 12‑month runway at its current burn rate.
The reduction in loss is largely attributable to the wind‑down of the Phase 2a influenza study and lower employee‑related expenses. Management emphasized that the company’s norovirus human challenge study for CDI‑988 is underway at Emory University School of Medicine, with healthy subjects being inoculated with the GII.2 (Snow Mountain Virus) strain under highly controlled conditions. The company also highlighted the continued development of its influenza candidate CC‑42344, noting that the initial Phase 2a study completed with favorable safety data but inconclusive efficacy due to trial conduct issues.
Cocrystal’s leadership reiterated the need for additional capital to sustain its clinical program. “Norovirus remains a significant and underserved market. Developing an effective norovirus antiviral or vaccine has been challenging due to the high genetic and antigenic diversity of norovirus and lack of simple in vitro cell‑based assays and animal model system. Using our proprietary structure‑based drug discovery platform technology, we developed CDI‑988 as a direct‑acting, oral antiviral that targets a highly conserved region of the viral 3CL protease found in all known norovirus strains. As a pan‑viral 3CL protease inhibitor, CDI‑988 also holds potential as a broad‑spectrum antiviral effective against coronaviruses,” said Sam Lee, Ph.D., President and co‑CEO.
The company’s financial position underscores ongoing challenges: zero revenue, a modest cash balance, and a need for further financing. While cost reductions have improved the loss profile, the absence of product revenue and the requirement for additional capital highlight the company’s continued reliance on external funding to advance its pipeline.
The sentiment surrounding the announcement is neutral to slightly negative, reflecting the company’s improved but still negative financial performance and the need for future capital.
-3
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.